了解难治性抑郁症患者抑郁症状严重程度与医疗费用的关系。

Frances L Lynch, John F Dickerson, Maureen O'Keeffe-Rosetti, Wing Chow, Jacqueline Pesa
{"title":"了解难治性抑郁症患者抑郁症状严重程度与医疗费用的关系。","authors":"Frances L Lynch,&nbsp;John F Dickerson,&nbsp;Maureen O'Keeffe-Rosetti,&nbsp;Wing Chow,&nbsp;Jacqueline Pesa","doi":"10.4088/JCP.21m13976","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> To examine whether measures of depression symptom severity could improve understanding of health care costs for patients with major depressive disorder (MDD) or treatment-resistant depression (TRD) from the health plan perspective.</p><p><p><b><i>Methods:</i></b> In this retrospective cohort study within an integrated health system, cohorts consisted of 2 mutually exclusive groups: (1) adults with TRD based on a standard treatment algorithm and (2) adults with MDD, but no TRD, identified through <i>ICD-9/10-CM</i> codes. Depression severity was measured using the Patient Health Questionnaire-9 (PHQ-9). Patterns of health care resource utilization (HRU) and costs were compared between the TRD and MDD groups overall and within the groups at different symptom levels. A general linear model with a γ distribution and log link for cost outcomes, logistic regression for binary outcomes, and negative binomial regression for count outcomes were used.</p><p><p><b><i>Results:</i></b> Patients with TRD (n = 24,534) had greater comorbidity than those in the MDD group (n = 17,628). Mean age in the TRD group was 52.8 years versus 48.2 for MDD (<i>P</i> < .001). Both groups were predominantly female (TRD: 72.8% vs MDD: 66.9%; <i>P</i> < .001). Overall, the TRD group had greater costs than the MDD group, with 1.23 times (95% CI, 1.21-1.26; <i>P</i> < .001) greater total cost on average over 1 year following index date. Within both groups, those with severe symptoms had greater total mean (SD) costs (TRD: moderate: $12,429 [$23,900] vs severe: $13,344 [$22,895], <i>P</i> < .001; low: $12,220 [$31,864] vs severe: $13,344 [$22,895], <i>P</i> < .001; MDD: moderate: $8,899 [$20,755] vs severe: $10,098 [$22,853]; <i>P</i> < .001; low: $8,752 [$25,800] vs severe: $10,098 [$22,853], <i>P</i> < .001).</p><p><p><b><i>Conclusions:</i></b> MDD and TRD impose high costs for health systems, with increasing costs as PHQ-9 symptom severity rises. Better understanding of subgroups with different symptom levels could improve clinical care by helping target interventions.</p>","PeriodicalId":516853,"journal":{"name":"The Journal of Clinical Psychiatry","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Understanding the Relationship Between Depression Symptom Severity and Health Care Costs for Patients With Treatment-Resistant Depression.\",\"authors\":\"Frances L Lynch,&nbsp;John F Dickerson,&nbsp;Maureen O'Keeffe-Rosetti,&nbsp;Wing Chow,&nbsp;Jacqueline Pesa\",\"doi\":\"10.4088/JCP.21m13976\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Objective:</i></b> To examine whether measures of depression symptom severity could improve understanding of health care costs for patients with major depressive disorder (MDD) or treatment-resistant depression (TRD) from the health plan perspective.</p><p><p><b><i>Methods:</i></b> In this retrospective cohort study within an integrated health system, cohorts consisted of 2 mutually exclusive groups: (1) adults with TRD based on a standard treatment algorithm and (2) adults with MDD, but no TRD, identified through <i>ICD-9/10-CM</i> codes. Depression severity was measured using the Patient Health Questionnaire-9 (PHQ-9). Patterns of health care resource utilization (HRU) and costs were compared between the TRD and MDD groups overall and within the groups at different symptom levels. A general linear model with a γ distribution and log link for cost outcomes, logistic regression for binary outcomes, and negative binomial regression for count outcomes were used.</p><p><p><b><i>Results:</i></b> Patients with TRD (n = 24,534) had greater comorbidity than those in the MDD group (n = 17,628). Mean age in the TRD group was 52.8 years versus 48.2 for MDD (<i>P</i> < .001). Both groups were predominantly female (TRD: 72.8% vs MDD: 66.9%; <i>P</i> < .001). Overall, the TRD group had greater costs than the MDD group, with 1.23 times (95% CI, 1.21-1.26; <i>P</i> < .001) greater total cost on average over 1 year following index date. Within both groups, those with severe symptoms had greater total mean (SD) costs (TRD: moderate: $12,429 [$23,900] vs severe: $13,344 [$22,895], <i>P</i> < .001; low: $12,220 [$31,864] vs severe: $13,344 [$22,895], <i>P</i> < .001; MDD: moderate: $8,899 [$20,755] vs severe: $10,098 [$22,853]; <i>P</i> < .001; low: $8,752 [$25,800] vs severe: $10,098 [$22,853], <i>P</i> < .001).</p><p><p><b><i>Conclusions:</i></b> MDD and TRD impose high costs for health systems, with increasing costs as PHQ-9 symptom severity rises. Better understanding of subgroups with different symptom levels could improve clinical care by helping target interventions.</p>\",\"PeriodicalId\":516853,\"journal\":{\"name\":\"The Journal of Clinical Psychiatry\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Clinical Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4088/JCP.21m13976\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Clinical Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4088/JCP.21m13976","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

目的:探讨抑郁症状严重程度的测量是否能从健康计划的角度提高重性抑郁症(MDD)或难治性抑郁症(TRD)患者对医疗费用的认识。方法:在一个综合卫生系统内的回顾性队列研究中,队列由两个相互排斥的组组成:(1)根据标准治疗算法患有TRD的成年人;(2)通过ICD-9/10-CM代码识别的患有重度抑郁症但没有TRD的成年人。使用患者健康问卷-9 (PHQ-9)测量抑郁严重程度。比较TRD组和MDD组整体及组内不同症状水平的卫生保健资源利用模式和费用。成本结果采用γ分布和对数链接的一般线性模型,二元结果采用逻辑回归,计数结果采用负二项回归。结果:TRD患者(n = 24,534)的合并症高于MDD组(n = 17,628)。TRD组的平均年龄为52.8岁,MDD组为48.2岁(P P P P P P P P P)结论:MDD和TRD给卫生系统带来了高昂的成本,随着PHQ-9症状严重程度的增加,成本也在增加。更好地了解不同症状水平的亚组可以通过帮助有针对性的干预来改善临床护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Understanding the Relationship Between Depression Symptom Severity and Health Care Costs for Patients With Treatment-Resistant Depression.

Objective: To examine whether measures of depression symptom severity could improve understanding of health care costs for patients with major depressive disorder (MDD) or treatment-resistant depression (TRD) from the health plan perspective.

Methods: In this retrospective cohort study within an integrated health system, cohorts consisted of 2 mutually exclusive groups: (1) adults with TRD based on a standard treatment algorithm and (2) adults with MDD, but no TRD, identified through ICD-9/10-CM codes. Depression severity was measured using the Patient Health Questionnaire-9 (PHQ-9). Patterns of health care resource utilization (HRU) and costs were compared between the TRD and MDD groups overall and within the groups at different symptom levels. A general linear model with a γ distribution and log link for cost outcomes, logistic regression for binary outcomes, and negative binomial regression for count outcomes were used.

Results: Patients with TRD (n = 24,534) had greater comorbidity than those in the MDD group (n = 17,628). Mean age in the TRD group was 52.8 years versus 48.2 for MDD (P < .001). Both groups were predominantly female (TRD: 72.8% vs MDD: 66.9%; P < .001). Overall, the TRD group had greater costs than the MDD group, with 1.23 times (95% CI, 1.21-1.26; P < .001) greater total cost on average over 1 year following index date. Within both groups, those with severe symptoms had greater total mean (SD) costs (TRD: moderate: $12,429 [$23,900] vs severe: $13,344 [$22,895], P < .001; low: $12,220 [$31,864] vs severe: $13,344 [$22,895], P < .001; MDD: moderate: $8,899 [$20,755] vs severe: $10,098 [$22,853]; P < .001; low: $8,752 [$25,800] vs severe: $10,098 [$22,853], P < .001).

Conclusions: MDD and TRD impose high costs for health systems, with increasing costs as PHQ-9 symptom severity rises. Better understanding of subgroups with different symptom levels could improve clinical care by helping target interventions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信